Desperate Families Chase Unproven Stem Cell Infusions for Autism as US Oversight Loosens
A Guardian investigation shows a booming US market for unapproved stem cell infusions marketed to autistic children, with families paying tens of thousands despite scant evidence of effectiveness and notable safety concerns. The piece links this growth to political moves by RFK Jr and allies to loosen FDA oversight, describes state efforts like Florida’s permissive stance, and contrasts hopeful anecdotes with controlled trials (Duke and Sutter Health) that found little to no autism improvement, highlighting the risk of exploitation for vulnerable families while regulators grapple with how to respond.
